Translational Psychiatry
October 8, 2026
Friederike Holze, Kristian Larsen, Brice Ozenne et al.
Abstract Classic psychedelics, including lysergic acid diethylamide (LSD), are currently under investigation for the treatment of major depressive disorder (MDD). Cognitive dysfunction is common in MDD, but effects of psychedelic treatment on cognitive brain function, measured by magnetic resonance imaging, are sparsely reported. The present study investigated effects of LSD treatment on...
Translational Psychiatry
October 6, 2026
Nadia S. Hejazi, Mina Kheirkhah, Robin Chholak et al.
Insomnia and anxiety frequently co-occur with treatment-resistant depression (TRD). This study examined short-term changes in depression, anxiety, and insomnia symptoms post-ketamine in TRD and their inter-relationships. Seventy-one patients with TRD were assessed at baseline and 24 h after intravenous ketamine (0.5 mg/kg). Depression, anxiety, and insomnia were measured using the...
Brain Research Bulletin
October 6, 2026
Ziyi Hua, Yongqiang Shu, Li Li et al.
INTRODUCTION: This study investigated changes in multiband amplitude of low-frequency fluctuations in patients with major depressive disorder following a 2-week combination treatment regimen of esketamine and sertraline, and examined the associations between ALFF changes and clinical symptom improvement. METHODS: Forty patients with major depressive disorder (MDD) received esketamine (0.25...
Psychological Medicine
October 6, 2026
Avery Chan Eun, Kevin H. Yang, Joseph J Palamar
Psilocybin use has increased in the US alongside promising therapeutic potential for depression, raising concerns that individuals may forgo conventional mental health treatment for unsupervised psilocybin use. However, no nationally representative studies have examined whether psilocybin use is associated with differential treatment utilization or perceived unmet need for mental health care...
Cogent Arts and Humanities
October 5, 2026
Khaled Al-Kassimi, Layal Hmaidi
Mainstream secular psychology is grounded in an epistemological framework that privileges reason while largely excluding revelation, thereby limiting its capacity to engage the spiritual dimensions of contemporary mental health and socio-political crises. Yet recent decades have witnessed growing scholarly and clinical interest in non-secular epistemologies that affirm the spiritual essence of...
Research Square
October 5, 2026
Anette Kjellgren, Johan Lundberg, Hampus Yngwe et al.
preprint
Abstract Psilocybin treatment has emerged as a promising intervention for Major Depressive Disorder (MDD). However, the contribution of psychotherapeutic support to treatment outcomes remains unclear. This study explored therapists' descriptions of their work during a randomized, double-blind, placebo-controlled psilocybin treatment phase II trial for MDD. Nine therapists participated in...
Pharmacopsychiatry
October 2, 2026
Masami Murao, Daiki Setoyama, Yasuyuki Matsumoto et al.
Abstract This study investigated the antisuicidal effects of repeated intravenous ketamine in patients with treatment-resistant depression and explored associations between suicidal ideation and temporal changes in selected plasma biomarkers to identify potential biomarkers. This secondary analysis of an open-label trial included outpatients with treatment-resistant depression who received four...
Health science reports
October 1, 2026
Naya Saadeh, Elie Atallah, Mirna A. Fawaz et al.
ABSTRACT Background and Aims Somatization, the physical manifestation of emotional and psychological distress, is a prevalent issue in populations exposed to war and trauma. War‐related nightmares are common among displaced individuals and are linked to depression, anxiety, and somatization. Yet, the indirect role of depression‐anxiety in the association between war‐related nightmares and...
Current Psychology
October 1, 2026
Mary-Anne Kate, Benjamin Dixon, David L. Hegarty et al.
Abstract: This study examined the relationship between depression and dissociation by assessing how specific dissociative symptoms vary with depression severity in a large Australian clinical sample. A total of 5,384 adults receiving mental health care completed the Depression Anxiety Stress Scales-21 (DASS-21) and the Multidimensional Inventory of Dissociation-60 (MID-60). Analyses included...
International Journal of Pharmaceutical and Clinical Research
October 1, 2026
H Gayathri, J Nivedhya, K Purushothama Reddy et al.
Aim: To assess the effectiveness of ketamine-based treatment for adults with treatment-resistant depression in terms of the persistence of antidepressant responses or remission after treatment discontinuation. Data Sources: PubMed/MEDLINE database search was performed to select randomized clinical trials that assessed the effect of ketamine interventions on TRD in adults. Study Selection: The...
Journal of Psychiatric Research
October 1, 2026
Erica Kaczmarek, Sabrina Wong, Noah Chisamore et al.
Background Anhedonia is a debilitating core feature of mood disorders, and is associated with significant functional impairment and poor quality of life. Psilocybin has recently emerged as a novel antidepressant treatment in MDD, however, its effects on anhedonia specifically have yet to be systematically reviewed. This review evaluates available clinical and pre-clinical research, exploring...
Psychedelics
October 1, 2026
David S. Mathai, Brian Pilecki, Hadi Zaki et al.
In 2019, the U.S. Food and Drug Administration (FDA) approved a patented formulation and delivery method of esketamine, the S-enantiomer of ketamine, for patients with treatment-resistant depression (TRD). While ketamine-based treatments share similarities with serotonin 2 A receptor-mediated “classic psychedelics” like psilocybin regarding subjective drug effects and stimulation of...
Psychedelics
October 1, 2026
Lorenzo Miller, Cordelia Kuiper Rauch, Keren Chen et al.
Background Psilocybin-assisted therapy has shown robust antidepressant effects among individuals with major depressive disorder (MDD); however, mechanisms of the treatment remain unclear. Depression has been associated with diminished feelings of connectedness to oneself, others, and the world, and psilocybin is thought to facilitate connectedness. This analysis of an open-label trial of...
Journal of Affective Disorders Reports
October 1, 2026
Kevin Byrne, Madeleine Odette, Eric L Garland et al.
ABSTRACT Background Healthcare workers experienced amplified depression and burnout during COVID-19. Both Mindfulness Based Stress Reduction (MBSR) and psilocybin have been shown to reduce depressive symptoms in this population, however the psychological mechanisms by which adding psilocybin to mindfulness training improves depression and trait mindfulness remain incompletely characterized....
Korea Exercise Rehabilitation Welfare Association
September 30, 2026
Do-Hyeok Jang, Sungh-Ho Hwang
This meta-analysis aimed to examine the effects of meditation-based interventions on psychological and physical outcomes in cancer patients. A total of 25 studies were included after a systematic literature search. Random-effects models were used to calculate pooled effect sizes (Hedges’ g), and meta-regression analyses were conducted to explore the moderating effects of the number of sessions,...
Clinical Psychology and Special Education
September 30, 2026
R. Ghorbani, N. Vahidi, Sh. Tamannaeifar et al.
Context and relevance. Emotion regulation and mindfulness are trans-diagnostic mechanisms underlying internalizing disorders such as Obsessive-Compulsive Disorder (OCD) and Major Depressive Disorder (MDD), having a significant influence on symptoms intensity and therapeutic effectiveness. Given the biological and phenomenological intersections as well as the high comorbidity between OCD and...
Preprints.org
September 29, 2026
Mouhammad Ousmane Ndiaye
preprint
A substantial proportion of patients with posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) do not respond to first-line treatment. Approximately 40% of PTSD patients do not respond to first-line psychotherapy, and 30.9% of MDD patients meet criteria for treatment-resistant depression. Yet standard polysomnography in these patients frequently shows REM sleep that appears...
The International Journal of Medical Science and Health Research
September 29, 2026
Arby Shafara Sekundaputra
Introduction: Treatment-resistant depression (TRD) affects approximately one-third of patients with major depressive disorder and accounts for disproportionate disability and mortality. Electroconvulsive therapy (ECT) has long been the definitive intervention, whereas subanaesthetic intravenous ketamine has emerged as a rapid-acting alternative. Direct head-to-head evidence has accumulated...
CNS Spectrums
September 28, 2026
Magda Malewska-Kasprzak, Filip Rybakowski, Monika Dmitrzak-Weglarz
Intravenous ketamine is a rapid-acting intervention for treatment-resistant depression (TRD) in adults with major depressive disorder and bipolar disorder (BD). While efficacy is established, a comprehensive integration of clinical, neurophysiological, biomarker, metabolic, and cognitive predictors remains lacking, limiting precision CNS-targeted therapy. To synthesize recent evidence on...
Progress in neuro-psychopharmacology & biological psychiatry
September 26, 2026
Kuan-I Liu, Wei-Chen Lin, Cheng-Ta Li et al.
We examined symptom-level treatment effects and exploratory symptom networks after ketamine in treatment-resistant depression. This post hoc analysis pooled 132 participants assigned to ketamine 0.5 mg/kg or protocol-specific control (66 each) from saline-controlled 2017 and midazolam-controlled 2023 trials. Baseline- and trial-adjusted models assessed Montgomery-Åsberg Depression Rating Scale...